SE9803772D0 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
SE9803772D0
SE9803772D0 SE9803772A SE9803772A SE9803772D0 SE 9803772 D0 SE9803772 D0 SE 9803772D0 SE 9803772 A SE9803772 A SE 9803772A SE 9803772 A SE9803772 A SE 9803772A SE 9803772 D0 SE9803772 D0 SE 9803772D0
Authority
SE
Sweden
Prior art keywords
omeprazole
active ingredient
core material
single enantiomers
pharmaceutical formulation
Prior art date
Application number
SE9803772A
Other languages
English (en)
Swedish (sv)
Inventor
Pontus Bergstrand
Peter Wang
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9803772(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9803772A priority Critical patent/SE9803772D0/xx
Publication of SE9803772D0 publication Critical patent/SE9803772D0/xx
Priority to CNB998128937A priority patent/CN1160062C/zh
Priority to PT99971703T priority patent/PT1124539E/pt
Priority to BR9915087-5A priority patent/BR9915087A/pt
Priority to ES99971703T priority patent/ES2201837T3/es
Priority to SI9930387T priority patent/SI1124539T1/xx
Priority to DE69909316T priority patent/DE69909316T2/de
Priority to EP99971703A priority patent/EP1124539B1/fr
Priority to AT99971703T priority patent/ATE244002T1/de
Priority to PCT/SE1999/001989 priority patent/WO2000027366A1/fr
Priority to CA002346988A priority patent/CA2346988C/fr
Priority to JP2000580597A priority patent/JP5412021B2/ja
Priority to IL14247499A priority patent/IL142474A0/xx
Priority to US09/485,218 priority patent/US6428810B1/en
Priority to AU14346/00A priority patent/AU774278B2/en
Priority to DK99971703T priority patent/DK1124539T3/da
Priority to NZ510993A priority patent/NZ510993A/en
Priority to KR1020017005682A priority patent/KR100627205B1/ko
Priority to IL142474A priority patent/IL142474A/en
Priority to ZA200103336A priority patent/ZA200103336B/en
Priority to NO20012222A priority patent/NO320056B1/no
Priority to HK02100762.4A priority patent/HK1039070B/zh
Priority to JP2011215798A priority patent/JP2012031189A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9803772A 1998-11-05 1998-11-05 Pharmaceutical formulation SE9803772D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE9803772A SE9803772D0 (sv) 1998-11-05 1998-11-05 Pharmaceutical formulation
NZ510993A NZ510993A (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole, a substituted pyridylsulfinylbenzimidazole a gastric acid secretion inhibitor, where the storage period is extended
KR1020017005682A KR100627205B1 (ko) 1998-11-05 1999-11-03 오메프라졸을 포함하는 제약 제형
PCT/SE1999/001989 WO2000027366A1 (fr) 1998-11-05 1999-11-03 Formulation pharmaceutique contenant de l'omeprazole
IL14247499A IL142474A0 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole
BR9915087-5A BR9915087A (pt) 1998-11-05 1999-11-03 Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem
ES99971703T ES2201837T3 (es) 1998-11-05 1999-11-03 Formulacion farmaceutica que comprende omeprazol.
SI9930387T SI1124539T1 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole
DE69909316T DE69909316T2 (de) 1998-11-05 1999-11-03 Pharmazeutische formulierung mit omeprazol
EP99971703A EP1124539B1 (fr) 1998-11-05 1999-11-03 Formulation pharmaceutique contenant de l'omeprazole
AT99971703T ATE244002T1 (de) 1998-11-05 1999-11-03 Pharmazeutische formulierung mit omeprazol
CNB998128937A CN1160062C (zh) 1998-11-05 1999-11-03 包含奥美拉唑的药用制剂
CA002346988A CA2346988C (fr) 1998-11-05 1999-11-03 Formulation pharmaceutique contenant de l'omeprazole
JP2000580597A JP5412021B2 (ja) 1998-11-05 1999-11-03 オメプラゾール含有医薬製剤
PT99971703T PT1124539E (pt) 1998-11-05 1999-11-03 Formulacao farmaceutica compreendendo omeprazole
US09/485,218 US6428810B1 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole
AU14346/00A AU774278B2 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole
DK99971703T DK1124539T3 (da) 1998-11-05 1999-11-03 Farmaceutisk formulering der omfatter omeprazol
IL142474A IL142474A (en) 1998-11-05 2001-04-05 A pharmaceutical formulation containing omeprazole
ZA200103336A ZA200103336B (en) 1998-11-05 2001-04-24 Pharmaceutical formulation comprising omeprazole.
NO20012222A NO320056B1 (no) 1998-11-05 2001-05-04 Farmasoytisk formulering innbefattende omeprazol, fremgangsmate til fremstilling derav, anvendelse av HPC i formuleringen, samt anvendelse av formuleringen til behandling av gastrointestinale sykdommer.
HK02100762.4A HK1039070B (zh) 1998-11-05 2002-01-31 包含奧美拉唑的藥劑
JP2011215798A JP2012031189A (ja) 1998-11-05 2011-09-30 オメプラゾール含有医薬製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803772A SE9803772D0 (sv) 1998-11-05 1998-11-05 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9803772D0 true SE9803772D0 (sv) 1998-11-05

Family

ID=20413180

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803772A SE9803772D0 (sv) 1998-11-05 1998-11-05 Pharmaceutical formulation

Country Status (20)

Country Link
US (1) US6428810B1 (fr)
EP (1) EP1124539B1 (fr)
JP (2) JP5412021B2 (fr)
KR (1) KR100627205B1 (fr)
CN (1) CN1160062C (fr)
AT (1) ATE244002T1 (fr)
AU (1) AU774278B2 (fr)
BR (1) BR9915087A (fr)
CA (1) CA2346988C (fr)
DE (1) DE69909316T2 (fr)
DK (1) DK1124539T3 (fr)
ES (1) ES2201837T3 (fr)
HK (1) HK1039070B (fr)
IL (2) IL142474A0 (fr)
NO (1) NO320056B1 (fr)
NZ (1) NZ510993A (fr)
PT (1) PT1124539E (fr)
SE (1) SE9803772D0 (fr)
WO (1) WO2000027366A1 (fr)
ZA (1) ZA200103336B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
US6418968B1 (en) 2001-04-20 2002-07-16 Nanostream, Inc. Porous microfluidic valves
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
ES2311073T3 (es) 2001-09-28 2009-02-01 Mcneil-Ppc, Inc. Forma de dosificacion que tiene un nucleo interno y un revestimiento externo.
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
WO2003049693A2 (fr) * 2001-12-06 2003-06-19 Wyeth Procede et composition permettant d'induire une perte de poids
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
BR0314356A (pt) * 2002-09-16 2005-07-19 Wyeth Corp Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
WO2004089333A2 (fr) * 2003-02-28 2004-10-21 Cadila Healthcare Limited Formulation de benzimidazole stable
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
EP2068841B1 (fr) 2006-10-05 2018-09-26 Santarus, Inc. Nouvelles formulations pour une libération immédiate d'inhibiteurs de pompe à protons et procédés d'utilisation de ces formulations
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
EP2486910A3 (fr) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Appareil comprenant plusieurs chambres et une tête de distribution
CN104940127A (zh) * 2007-09-28 2015-09-30 西梯茜生命工学股份有限公司 含有埃索美拉唑的药物组合物
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2445344A4 (fr) * 2009-06-25 2013-01-23 Pozen Inc Procédé de traitement d'un patient nécessitant une thérapie à l'aspirine
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
WO2016174664A1 (fr) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017112627A1 (fr) * 2015-12-22 2017-06-29 Shell Oil Company Procédé de préparation d'un polycarbonate fondu
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
DK0723436T3 (da) * 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation

Also Published As

Publication number Publication date
NO20012222D0 (no) 2001-05-04
US6428810B1 (en) 2002-08-06
NZ510993A (en) 2003-08-29
NO20012222L (no) 2001-07-02
PT1124539E (pt) 2003-11-28
DK1124539T3 (da) 2003-10-06
JP2012031189A (ja) 2012-02-16
AU774278B2 (en) 2004-06-24
CA2346988C (fr) 2009-02-10
EP1124539A1 (fr) 2001-08-22
IL142474A0 (en) 2002-03-10
AU1434600A (en) 2000-05-29
DE69909316D1 (de) 2003-08-07
ES2201837T3 (es) 2004-03-16
ZA200103336B (en) 2002-07-24
IL142474A (en) 2007-08-19
KR20010075685A (ko) 2001-08-09
EP1124539B1 (fr) 2003-07-02
CN1325300A (zh) 2001-12-05
ATE244002T1 (de) 2003-07-15
HK1039070A1 (en) 2002-04-12
NO320056B1 (no) 2005-10-17
BR9915087A (pt) 2001-07-17
JP5412021B2 (ja) 2014-02-12
DE69909316T2 (de) 2004-06-03
HK1039070B (zh) 2003-12-19
CA2346988A1 (fr) 2000-05-18
KR100627205B1 (ko) 2006-09-22
JP2002529397A (ja) 2002-09-10
WO2000027366A1 (fr) 2000-05-18
CN1160062C (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
SE9803772D0 (sv) Pharmaceutical formulation
YU60899A (sh) Farmaceutska formulacija omeprazola
CA2376226A1 (fr) Nouvelle formulation
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
NZ512683A (en) Taste-masked pharmaceutical particles that are suitable for making chewable tablets
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
AU6998796A (en) Novel composition containing an acid-labile benzimidazole and process for its preparation
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
CA2277017A1 (fr) Forme galenique pharmaceutique a liberation rapide et masquant le gout
ES2185452A1 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
IE64850B1 (en) Therapeutically active substituted benzimidazole and process for its preparation
YU28404A (sh) Brzo topljiva formulacija za oralno doziranje